Commentary on the NeBoP score – a clinical prediction test for children with Lyme neuroborreliosis

Barbro H Skogman1, Johanna Sjöwall2, Per-Eric Lindgren3

1Paediatric clinic, Falun General Hospital and Center for Clinical Research (CKF) Dalarna – Uppsala University, Sweden
2Clinical of Infectious Diseases, Linköping University Hospital and Division of Clinical Immunology, Department of Clinical and Experimental Medicine, University of Linköping, Sweden
3Medical Microbiology, Department of Clinical and Experimental Medicine, University of Linköping, S-581 85 Linköping, Sweden and Microbiological Laboratory, Medical Services, County Hospital Ryhov, Sweden


Background

The diagnosis of Lyme neuroborreliosis in Europe is based on clinical symptoms and laboratory data, such as pleocytosis and anti-\textit{Borrelia} antibodies in serum and CSF according to guidelines\textsuperscript{1}. However, the decision to start antibiotic treatment on admission cannot be based on \textit{Borrelia} serology since results are not available at the time of lumbar puncture. Therefore, an early prediction test would be useful in clinical practice. Previous studies have suggested different clinical prediction rules but patients have not been representative of all children with Lyme neuroborreliosis in Europe\textsuperscript{2-4}. We can here present a study based on a large representative sample of children being evaluated for Lyme neuroborreliosis in a European Lyme endemic area.

Material and Method

Clinical and laboratory data were collected retrospectively from a cohort of children being evaluated for Lyme neuroborreliosis in Southeast Sweden. A clinical neuroborreliosis prediction test, the NeBoP score, was designed to differentiate between a high and a low risk of having Lyme neuroborreliosis. It included variables such as acute facial nerve palsy (or other cranial nerve palsy), fever, fatigue, erythema migrans and/or lymphocytoma and pleocytosis in CSF (with total cell count ≥ 5 × 10\textsuperscript{6}/L with ≥ 90 % mononuclear cells) (Figure 1). A score of ≥ 3 points was considered as positive test. The NeBoP score was prospectively validated in another cohort of children being evaluated for Lyme neuroborreliosis in Central and Southeast Sweden (n=190) and controls with other specific diagnoses (n= 49).

Results

The sensitivity of the NeBoP score was 90% (CI 95%; 82-99%) and the specificity was 90% (CI 95%; 85-96%). Thus, the diagnostic accuracy (i.e. how the test correctly discriminates patients from controls) was 90% and the area under the curve in a ROC analysis was 0.95. The positive predictive value (PPV) was 0.83 (CI 95%; 0.75 – 0.93) and the negative predictive value (NPV) was 0.95 (CI 95%; 0.90 – 0.99).
Our results support that this clinical predictive test, the NeBoP score, could be useful for pediatricians in early assessment of children being evaluated for Lyme neuroborreliosis. However, the NeBoP score cannot be recommended for Northern America due to differences in the clinical manifestations of Lyme neuroborreliosis, the occurrence of different tick vectors and different *Borrelia* species between the two continents. We also believe, based a NPV of 0.95 for the NeBoP score, that the test will be helpful for the pediatrician to correctly refrain from unnecessary antibiotic treatment on admission and consider other differential diagnoses while waiting for anti-*Borrelia* antibody results. This aspect is, in our opinion, also important in order to prevent over usage of antibiotics. Furthermore, other CNS infections should be evaluated in parallel to LNB.

**Conclusion**

The overall diagnostic performance of the NeBoP score is high (90%) and the test is suggested to be useful when evaluating children with Lyme neuroborreliosis in European Lyme endemic areas.

**Author’s comments**

A clinical prediction test would be useful also for adult patients being evaluated for Lyme neuroborreliosis, but such a test has to our knowledge not yet been developed.

**References**


